Due tothe paucity of available evidence, widespread use of empiric aspirin oranticoagulation is not recommended, though there is some evidence thattargeted PAH medications including parenteral epoprostenol, ET receptorantagonists and sGC stimulators may attenuate some of these derangements.High quality translational studies and clinical trials are required tofurther elucidate the role of platelets, coagulation and EVs in thepathobiology of PAH and their potential as biomarkers and therapeutictargets. The gene discussed is SGCB; the disease is pulmonary arterial hypertension.